{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:01:23Z","timestamp":1773216083334,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110567","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T16:55:09Z","timestamp":1688576109000},"page":"110567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["What exactly is the relationship between plasma cytokines and the clinical phenotype of primary sj\u00f6gren's syndrome? a single-centre retrospective study"],"prefix":"10.1016","volume":"122","author":[{"given":"Lijing","family":"Shang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2305-5886","authenticated-orcid":false,"given":"Mengjiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2023.110567_b0005","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"Eular sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Annals of the rheumatic diseases"},{"issue":"18","key":"10.1016\/j.intimp.2023.110567_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11185405","article-title":"Interferon gamma targeted therapy: is it justified in primary sj\u00f6gren's syndrome?","volume":"11","author":"Sebastian","year":"2022","journal-title":"Journal of clinical medicine"},{"key":"10.1016\/j.intimp.2023.110567_b0015","doi-asserted-by":"crossref","first-page":"5928232","DOI":"10.1155\/2021\/5928232","article-title":"Advances in pathogenesis of sj\u00f6gren's syndrome","volume":"2021","author":"Tian","year":"2021","journal-title":"Journal of immunology research"},{"issue":"11","key":"10.1016\/j.intimp.2023.110567_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/cells11111767","article-title":"Abnormal epigenetic regulations in the immunocytes of sj\u00f6gren's syndrome patients and therapeutic potentials","volume":"11","author":"Li","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.intimp.2023.110567_b0025","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/ard.2009.115378","article-title":"Cytokines in Sjogren's syndrome: potential therapeutic targets","volume":"69","author":"Roescher","year":"2010","journal-title":"Annals of the rheumatic diseases"},{"issue":"23","key":"10.1016\/j.intimp.2023.110567_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239172","article-title":"Innate immunity and biological therapies for the treatment of sj\u00f6gren's syndrome","volume":"21","author":"Srivastava","year":"2020","journal-title":"International journal of molecular sciences"},{"issue":"11","key":"10.1016\/j.intimp.2023.110567_b0035","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1136\/annrheumdis-2015-208504","article-title":"Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies","volume":"75","author":"Seror","year":"2016","journal-title":"Annals of the rheumatic diseases"},{"issue":"2","key":"10.1016\/j.intimp.2023.110567_b0040","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","article-title":"Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren's syndrome with EULAR primary Sj\u00f6gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)","volume":"75","author":"Seror","year":"2016","journal-title":"Annals of the rheumatic diseases"},{"issue":"11","key":"10.1016\/j.intimp.2023.110567_b0045","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/1744666X.2016.1199957","article-title":"Restoring regulation - IL-2 therapy in systemic lupus erythematosus","volume":"12","author":"Humrich","year":"2016","journal-title":"Expert review of clinical immunology"},{"key":"10.1016\/j.intimp.2023.110567_b0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pharmthera.2017.10.019","article-title":"Cytokines as therapeutic targets in primary sj\u00f6gren syndrome","volume":"184","author":"Retamozo","year":"2018","journal-title":"Pharmacology & therapeutics"},{"issue":"12","key":"10.1016\/j.intimp.2023.110567_b0055","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary sj\u00f6gren's syndrome","volume":"77","author":"Miao","year":"2018","journal-title":"Annals of the rheumatic diseases"},{"issue":"1","key":"10.1016\/j.intimp.2023.110567_b0060","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1038\/s41598-019-43714-5","article-title":"Elevated cytokine levels in tears and saliva of patients with primary sj\u00f6gren's syndrome correlate with clinical ocular and oral manifestations","volume":"9","author":"Chen","year":"2019","journal-title":"Scientific reports"},{"issue":"11","key":"10.1016\/j.intimp.2023.110567_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/biom10111539","article-title":"T Cells Subsets in the immunopathology and treatment of sjogren's syndrome","volume":"10","author":"R\u00edos-R\u00edos","year":"2020","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.intimp.2023.110567_b0070","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10753-021-01601-0","article-title":"Quantile-dependent expressivity of serum interleukin-6 concentrations as a possible explanation of gene-disease interactions, gene-environment interactions, and pharmacogenetic effects","volume":"45","author":"Williams","year":"2022","journal-title":"Inflammation"},{"issue":"6","key":"10.1016\/j.intimp.2023.110567_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105406","article-title":"Current and future treatment in primary sj\u00f6gren's syndrome - A still challenging development","volume":"89","author":"Ritter","year":"2022","journal-title":"Joint bone spine"},{"key":"10.1016\/j.intimp.2023.110567_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-209076","article-title":"Tocilizumab for refractory organising pneumonia associated with sj\u00f6gren's disease","author":"Justet","year":"2015","journal-title":"BMJ case reports"},{"key":"10.1016\/j.intimp.2023.110567_b0085","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.pediatrneurol.2017.05.015","article-title":"First pediatric patient with neuromyelitis optica and sj\u00f6gren syndrome successfully treated with tocilizumab","volume":"73","author":"Marino","year":"2017","journal-title":"Pediatric neurology"},{"issue":"2","key":"10.1016\/j.intimp.2023.110567_b0090","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/14397595.2013.861333","article-title":"Neuromyelitis optica spectrum disorder complicated with sjogren syndrome successfully treated with tocilizumab: A case report","volume":"26","author":"Komai","year":"2016","journal-title":"Modern rheumatology"},{"issue":"27","key":"10.1016\/j.intimp.2023.110567_b0095","doi-asserted-by":"crossref","first-page":"e16285","DOI":"10.1097\/MD.0000000000016285","article-title":"Refractory sj\u00f6gren's syndrome myelopathy successfully treated with subcutaneous tocilizumab: A case report","volume":"98","author":"Ishikawa","year":"2019","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.intimp.2023.110567_b0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Annals of the rheumatic diseases"},{"key":"10.1016\/j.intimp.2023.110567_b0105","doi-asserted-by":"crossref","first-page":"6658324","DOI":"10.1155\/2021\/6658324","article-title":"Increased CD4(+)CD8(+) double-Positive t cell in patients with primary sj\u00f6gren's syndrome correlated with disease activity","volume":"2021","author":"Wang","year":"2021","journal-title":"Journal of immunology research"},{"issue":"7","key":"10.1016\/j.intimp.2023.110567_b0110","first-page":"8391","article-title":"Cytokine expression in patients with interstitial lung disease in primary Sjogren's syndrome and its clinical significance","volume":"13","author":"Yang","year":"2021","journal-title":"American journal of translational research"},{"issue":"7","key":"10.1016\/j.intimp.2023.110567_b0115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.humimm.2015.06.009","article-title":"Analysis of IL10 haplotypes in primary sj\u00f6gren's syndrome patients from western mexico: Relationship with mRNA expression, IL-10 soluble levels, and autoantibodies","volume":"76","author":"V\u00e1zquez-Villamar","year":"2015","journal-title":"Human immunology"},{"issue":"12","key":"10.1016\/j.intimp.2023.110567_b0120","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41423-019-0227-z","article-title":"IL-10-producing regulatory B cells restrain the T follicular helper cell response in primary sj\u00f6gren's syndrome","volume":"16","author":"Lin","year":"2019","journal-title":"Cellular & molecular immunology"},{"issue":"2","key":"10.1016\/j.intimp.2023.110567_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020251","article-title":"The role of interferons in the pathogenesis of sj\u00f6gren's syndrome and future therapeutic perspectives","volume":"11","author":"Del Papa","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2023.110567_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11010003","article-title":"The clinical and immunological activity depending on the presence of interferon \u03b3 in primary sj\u00f6gren's syndrome-a pilot study","volume":"11","author":"Sebastian","year":"2021","journal-title":"Journal of clinical medicine"},{"key":"10.1016\/j.intimp.2023.110567_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106878","article-title":"Relationships between increased circulating YKL-40, IL-6 and TNF-\u03b1 levels and phenotypes and disease activity of primary Sj\u00f6gren's syndrome","volume":"88","author":"Chen","year":"2020","journal-title":"International immunopharmacology"},{"key":"10.1016\/j.intimp.2023.110567_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108758","article-title":"Association between IL-7 and primary sj\u00f6gren's syndrome: A single-center study and a systematic scoping review","volume":"108","author":"Liang","year":"2022","journal-title":"International immunopharmacology"},{"issue":"10","key":"10.1016\/j.intimp.2023.110567_b0145","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.autrev.2018.05.005","article-title":"Clinical and immunological parameters of sj\u00f6gren's syndrome","volume":"17","author":"Psianou","year":"2018","journal-title":"Autoimmunity reviews"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:20:40Z","timestamp":1736432440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923008901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":29,"alternative-id":["S1567576923008901"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110567","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What exactly is the relationship between plasma cytokines and the clinical phenotype of primary sj\u00f6gren's syndrome? a single-centre retrospective study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110567"}}